<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129945</url>
  </required_header>
  <id_info>
    <org_study_id>2014-1085</org_study_id>
    <secondary_id>UC Reliance 857</secondary_id>
    <nct_id>NCT03129945</nct_id>
  </id_info>
  <brief_title>Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor</brief_title>
  <official_title>Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the best medication to stop preterm labor.&#xD;
      Recent studies have identify nifedipine and indomethacin as the two medications that are most&#xD;
      likely to delay delivery for 48 hours, decrease maternal side effects and decrease some&#xD;
      complications related to preterm delivery to the neonate. Both of these medications are&#xD;
      commonly used to stop pre-term labor, therefore it has become our institution's standard to&#xD;
      use these two medications in the setting of preterm labor. There have been limited studies&#xD;
      comparing these two medications directly.&#xD;
&#xD;
      A total of 450 participants will be asked to participate across all study sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are about 10 million births that occur before 37 weeks (prior to full term gestation)&#xD;
      that occur annually worldwide. More than 1 million infants die from complications related to&#xD;
      preterm birth. Tocolytics, medications that stop preterm labor, have been well studied.&#xD;
      Results regarding prolongation of pregnancy are varied, but tocolytics have been shown to&#xD;
      delay delivery for 48 hours, allowing time to administer corticosteroids. ACOG (American&#xD;
      Congress of Obstetrics and Gynecologists) recommends giving tocolytics to provide time for&#xD;
      corticosteroid administration, transfer to tertiary level care and to allow for magnesium&#xD;
      infusion to protect the neonatal brain. Corticosteroid administration when the course is&#xD;
      completed (48 hours from first dose) decreases some of the major risks associated with&#xD;
      prematurity.&#xD;
&#xD;
      Recent meta-analyses have shown of the commonly used tocolytics, calcium channel blockers and&#xD;
      prostaglandin inhibitors ranked consistently among the top three medications in several&#xD;
      categories including delaying delivery by 48 hours. There have been only two published&#xD;
      randomized control studies to date that have directly compared these two tocolytics. These&#xD;
      studies lacked power and standardization to provide clinical guidelines. There is a high&#xD;
      neonatal mortality and morbidity along with exceedingly high hospital costs associated with&#xD;
      complications related to preterm birth, so it is important to intervene with superior&#xD;
      medications. Here the investigators propose a multi institutional (based within the&#xD;
      University of California system) randomized controlled study to directly compare nifedipine&#xD;
      (most commonly used calcium channel blocker) to indomethacin (most commonly used&#xD;
      prostaglandin inhibitor).&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The Investigator's objective is to compare the prolongation of pregnancy by 48 hours after&#xD;
      women are diagnosed with preterm labor prior to 32 weeks gestational age and treated with&#xD;
      either nifedipine or indomethacin. Investigators hypothesize that indomethacin will&#xD;
      significantly arrest preterm labor by 48 hours in more women compared to nifedipine. The&#xD;
      primary outcomes measures will be delaying preterm delivery by 48 hours; secondary outcomes&#xD;
      measures will include delay of delivery by 7 days and decreasing delivery before 37 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Actual">April 18, 2019</completion_date>
  <primary_completion_date type="Actual">April 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Delay of Preterm Delivery by 48 Hours.</measure>
    <time_frame>Participants will be followed for the duration of the hospital stay, an expected average of 1 week</time_frame>
    <description>1. To compare the prolongation of pregnancy by 48 hours after women are diagnosed with threatened preterm labor prior to 32 weeks gestational age and treated with either nifedipine or indomethacin. The primary outcome measured will be delay of (preterm delivery) by 48 hours.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Obstetric Labor, Premature</condition>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given this medication orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given this medication orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.</description>
    <arm_group_label>Nifedipine</arm_group_label>
    <other_name>Procardia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.</description>
    <arm_group_label>Indomethacin</arm_group_label>
    <other_name>Indocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy. A twin pregnancy reduced to singleton (either spontaneously or&#xD;
             therapeutically) before 140 weeks by gestational age (see dating below) is acceptable.&#xD;
&#xD;
          -  Gestational age at randomization between 240 weeks to 315 weeks by using the dating&#xD;
             determinations as below&#xD;
&#xD;
          -  Preterm labor with intact membranes. Preterm labor is defined as at least 6 regular&#xD;
             uterine contractions in 60 minutes either seen on tocodynamometer, palpated by health&#xD;
             providers and/or subjectively felt by the patient and at least one of the following:&#xD;
&#xD;
               1. Associated with cervical change by cervical dilation greater than or equal to 1cm&#xD;
                  OR effacement greater than or equal to 25 to 50%&#xD;
&#xD;
               2. Cervix greater than or equal to 2cm dilated on initial digital exam&#xD;
&#xD;
               3. At least 75% effaced on initial digital exam&#xD;
&#xD;
               4. Short cervical length (defined by each institution's policy) as obtained by&#xD;
                  transvaginal cervical sonography [in general, this is defined as a measurement of&#xD;
                  2.0 - 2.5 cm or less] and/or a positive fetal fibronectin test (defined as a&#xD;
                  level greater than 50ng/mL).&#xD;
&#xD;
          -  Intact membranes&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fetal demise, or known major fetal anomaly, including cardiac anomaly and hydrops&#xD;
&#xD;
          -  Maternal contraindication to nifedipine: preload cardiac lesions or maternal&#xD;
             hypotension (systolic blood pressure less than 100 or diastolic blood pressure less&#xD;
             than 60). A delayed dose can be given if blood pressure improves - it will be&#xD;
             documented if dose is delayed, how long from scheduled dose it was delayed and reason&#xD;
             for delay.&#xD;
&#xD;
          -  Maternal contraindication to indomethacin: platelet dysfunction or bleeding disorders,&#xD;
             hepatic dysfunction, gastrointestinal ulcerative disease, renal dysfunction and asthma&#xD;
&#xD;
          -  Obstetrical contraindication to tocolysis not already mentioned: non reassuring fetal&#xD;
             status, severe preeclampsia or eclampsia, maternal bleeding with hemodynamic&#xD;
             instability, chorioamnionitis, preterm premature rupture of membranes&#xD;
&#xD;
          -  Participation in another interventional study that influences neonatal morbidity or&#xD;
             mortality&#xD;
&#xD;
          -  Participation in this trial earlier in the pregnancy&#xD;
&#xD;
          -  Maternal allergy to either indomethacin or nifedipine&#xD;
&#xD;
          -  Maternal allergy to aspirin and other NSAIDs.&#xD;
&#xD;
          -  Maternal hypertension requiring treatment.&#xD;
&#xD;
          -  Maternal kidney disorder that would require adjustment in magnesium dosing.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah A Wing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Norton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gladys (Sandy) Ramos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aisling Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Veronique Tache, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <results_first_submitted>June 14, 2021</results_first_submitted>
  <results_first_submitted_qc>October 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Judith H Chung</investigator_full_name>
    <investigator_title>MD, Professor, Division of Maternal Fetal Medicine, Dept OBGYN</investigator_title>
  </responsible_party>
  <keyword>Obstetric Labor, Premature</keyword>
  <keyword>Tocolytic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03129945/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited from January 17, 2017, to February 24, 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nifedipine</title>
          <description>Participants will be given this medication orally&#xD;
Nifedipine: Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.</description>
        </group>
        <group group_id="P2">
          <title>Indomethacin</title>
          <description>Participants will be given this medication orally&#xD;
Indomethacin: Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nifedipine</title>
          <description>Participants will be given this medication orally&#xD;
Nifedipine: Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.</description>
        </group>
        <group group_id="B2">
          <title>Indomethacin</title>
          <description>Participants will be given this medication orally&#xD;
Indomethacin: Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Delay of Preterm Delivery by 48 Hours.</title>
        <description>1. To compare the prolongation of pregnancy by 48 hours after women are diagnosed with threatened preterm labor prior to 32 weeks gestational age and treated with either nifedipine or indomethacin. The primary outcome measured will be delay of (preterm delivery) by 48 hours.</description>
        <time_frame>Participants will be followed for the duration of the hospital stay, an expected average of 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nifedipine</title>
            <description>Participants will be given this medication orally&#xD;
Nifedipine: Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin</title>
            <description>Participants will be given this medication orally&#xD;
Indomethacin: Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Delay of Preterm Delivery by 48 Hours.</title>
          <description>1. To compare the prolongation of pregnancy by 48 hours after women are diagnosed with threatened preterm labor prior to 32 weeks gestational age and treated with either nifedipine or indomethacin. The primary outcome measured will be delay of (preterm delivery) by 48 hours.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected through study completion, for an average of 1 week.</time_frame>
      <desc>Adverse event definition did not differ from the clinicaltrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nifedipine</title>
          <description>Participants will be given this medication orally&#xD;
Nifedipine: Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.</description>
        </group>
        <group group_id="E2">
          <title>Indomethacin</title>
          <description>Participants will be given this medication orally&#xD;
Indomethacin: Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judith Chung</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>714-456-8695</phone>
      <email>judithc@hs.uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

